A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s diseaseStephen Salloway, Paul Aisen, Richard J. Perrin et al.|Nature Medicine|2021Cited by 364
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trialRandall J. Bateman, Bruno Dubois, Tammie L.S. Benzinger et al.|The Lancet Neurology|2025Cited by 39